Search

Results: 1

Cover Image for A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

Pradeep J Nathan, S Babli Millais, Alex Godwood, Odile Dewit, David M Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones, Geor Bakker, Paul T Maruff, Gregory A Light, Alastair JH Brown, Malcolm Peter Weir, Miles Congreve, Tim Tasker

Feb 23, 2022

Alzheimer's Disease Cogstate neuropsychological test battery HTL0018318 Attention cholinergic clinical trial Cognition Electrophysiology event related potential Memory muscarinic M1 receptor pharmacodynamic Safety symptomatic tolerability

Published by: